1 SOCIODEMOGRAPHIC CHARACTERISTICS OF SARS-COV-2 SEROSURVEILLANCE

2 STUDIES WITH DIVERSE RECRUITMENT STRATEGIES, CANADA, 2020 TO 2023

- 3 Matthew J. Knight¹, Yuan Yu¹, Jiacheng Chen¹, Sheila F. O'Brien^{2,3}, David L. Buckeridge^{1,4},
- 4 Carmen Charlton^{5,6}, W. Alton Russell^{1,4}
- 5 1. Department of Epidemiology, Biostatistics and Occupational Health, School of Population and
- 6 Global Health, McGill University, Montreal, Canada
- 7 2. Canadian Blood Services, Ottawa, Canada
- 8 3. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
- 9 4. COVID-19 Immunity Task Force, Montreal, Canada
- 10 5. Canadian Blood Services, Edmonton, Canada
- 11 6. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada
- 12 Corresponding author: Matthew J. Knight (matthew.knight@mail.mcgill.ca), +1-613-854-9571
- 13 Suite 1200, McGill College Avenue, Montreal, QC, Canada H3A 1G1
- 14 Keywords: Representativeness; Surveillance; COVID-19
- 15
- 15
- 16
- 17
- 18
- 19

20 ABSTRACT

21 Background. Serological testing was a key component of severe acute respiratory syndrome 22 coronavirus-2 (SARS-CoV-2) surveillance. Social distancing interventions, resource limitations, 23 and the need for timely data led to serosurveillance studies using a range of recruitment 24 strategies, which likely influenced study representativeness. Characterizing representativeness in 25 surveillance is crucial to identify gaps in sampling coverage and to assess health inequities. 26 Methods. We retrospectively analyzed three pre-existing longitudinal cohorts, two convenience 27 samples using residual blood, and one de novo probabilistic survey conducted in Canada 28 between April 2020 - November 2023. We calculated study specimen counts by age, sex, 29 urbanicity, race/ethnicity, and neighborhood deprivation quintiles. We derived a 'representation 30 ratio' as a simple metric to assess generalizability to a target population and various 31 sociodemographic strata. 32 **Results**. The six studies included 1,321,675 specimens. When stratifying by age group and sex, 33 65% of racialized minority subgroups were moderately underrepresented (representation ratio < 34 0.75). Representation was generally higher for older Canadians, urban neighborhoods, and 35 neighborhoods with low material deprivation. Rural representation was highest in a study that 36 used outpatient laboratory blood specimens. Racialized minority representation was highest in a 37 de novo probabilistic survey cohort. Conclusion. While no study had adequate representation of all subgroups, less traditional 38 39 recruitment strategies were more representative of some population dimensions. Understanding 40 demographic representativeness and barriers to recruitment are important considerations when 41 designing population health surveillance studies.

42

43 INTRODUCTION

44 Serological surveillance is a critical input to infectious disease control, including pandemic 45 preparedness and response. In 2020, Canada launched the largest serological surveillance 46 program in its history to monitor population immunity to severe acute respiratory syndrome 47 coronavirus-2 (SARS-CoV-2), informing COVID-19 epidemiology and antibody dynamics. 48 Between April 2020 and February 2021, many studies began testing blood specimens for SARS-49 CoV-2 antibodies [1–6]. Challenged by social distancing measures, studies used diverse 50 strategies to recruit participants or obtain blood samples. Recruitment strategy influences study 51 population's characteristics and the extent to which participants represent the general population 52 [7]. 53 54 Serosurveillance studies can be broadly categorized as convenience samples, de novo 55 probabilistic surveys, or pre-existing longitudinal cohorts. For SARS-CoV-2 serosurveillance, 56 many countries used convenience samples of residual blood specimens due to low operational 57 costs and ease of continued sample collection over time [1,2,8,9]. Convenience samples may 58 introduce selection bias if certain subpopulations are excluded or poorly represented [1,8]. 59 Probabilistic serosurveys, also deployed in many regions to monitor SARS-CoV-2, can mitigate 60 selection biases by using stratified, weight-based approaches to recruitment. De novo designs 61 allow tailoring recruitment to study objectives [4,5,10–12]. However, probabilistic designs are 62 time- and resource-intensive and are sometimes limited by low response rates [6,13]. Sampling 63 within pre-existing longitudinal cohorts can improve efficiency by leveraging an established 64 sampling frame and study infrastructure. But this precludes tailoring the sampling frame to the 65 current research question, and generalizability may be limited by inclusion criteria or attrition.

66
~ ~

67	In this study, we introduce a simple metric for diagnosing the representativeness of subgroups
68	within a study population. Using this metric, we evaluated the sociodemographic
69	representativeness of six SARS-CoV-2 serosurveillance studies with diverse recruitment
70	strategies by age, sex, race/ethnicity, urbanicity, and neighborhood measures of socioeconomic
71	deprivation. Our findings can inform serosurveillance study design for diverse pathogens.

72

73 METHODS

74 Data

75 We assessed representativeness by analyzing demographic data from six Canadian study 76 populations (Table 1). Here, we define a study to be representative if the sociodemographic 77 composition of the study population matched the census-based target population; we make no 78 assumptions of the sampling mechanism or inferential validity. This similarity suggests the 79 interpretation of an effect measure may be generalizable to the target population, but does not 80 assume the effect estimate, within an uncertainty interval, will be identical between the study and 81 target populations [14]. The six studies included one de novo cross-sectional probabilistic sample 82 (the Canadian COVID-19 Antibody and Health Survey 1 [CCAHS-1]), one open longitudinal 83 cohort recruited from a marketing research panel (Action to Beat Coronavirus study [Ab-C]), 84 two pre-existing closed longitudinal cohorts (the Canadian Longitudinal Study on Aging 85 COVID-19 Antibody Study [CLSA], the Canadian Partnership for Tomorrow's Health COVID-86 19 Antibody Study [CanPath]), and two serial cross-sectional convenience samples that used 87 residual blood from blood donations (Canadian Blood Services [CBS]) and specimens collected 88 for outpatient laboratory testing (Alberta Precision Laboratories [APL]). The included studies

89	tested specimens collected from April 2020 to November 2023 with sample sizes ranging from
90	11,050 (CCAHS-1) to 1,039,298 (CBS). Inclusion criteria and enrollment procedures have been
91	described previously [1,2,6,12,15,16]. This study was reported using the STrengthening the
92	Reporting of OBservational studies in Epidemiology checklist for cross-sectional studies [17].
93	
94	
95	
96	
97	
98	
99	
100	
101	
102	
103	
104	
105	
106	
107	
108	
109	
110	
111	
112	
113	

Study	Design	Age	Region	Specimen type	Study time and size	De novo recruitment
Action to Beat Coronavirus (Ab-C)	Pre-existing longitudinal open research cohort	≥18	AB, BC, MB, NB, NL, NS, ON, PE, QC, SK, YT ^a	Dried blood spot	25,110 specimens from 10,621 participants May 2020 - April 2022	No
Alberta Precision Laboratories (APL)	Serial cross- sectional convenience sample	≥ 0	AB	Heparinized plasma Plasma Serum	210,905 specimens from 187,887 participants April 2020 - October 2022	No
Canadian Blood Services (CBS)	Serial cross- sectional random sample	≥18	AB, BC, MB, NB, NL, NS, ON, PE, SK	Serum	1,035,580 specimens from 446,187 participants May 2020 - November 2023	No
Canadian Covid-19 Antibody and Health Survey 1 (CCAHS-1)	Prospective cross- sectional cohort with direct (ages 1-24) or multi- stage (ages ≥ 25) sampling	≥1	AB, BC, MB, NB, NL, NT, NS, NU, ON, PE, QC, SK, YT	Dried blood spot	11,050 specimens from 11,050 participants November 2020 - April 2021	Yes
Canadian Longitudinal Study on Aging (CLSA) ^b	Pre-existing longitudinal closed research cohort	≥ 51	AB, BC, MB, NB, NL, NS, ON, PE, QC, SK	Dried blood spot Plasma	17,310 specimens from 17,310 participants October 2020 - August 2021	No
Canadian Partnership for Tomorrow's Health (CanPath) ^c	Pre-existing longitudinal closed research cohort	≥25	AB, BC, MB, NB, NL, NS, ON, PE, QC	Dried blood spot	21,720 specimens from 21,717 participants February 2021 - November 2021	No

114 **Table 1**: Summary of SARS-CoV-2 serological study designs included in the study.

115 *Notes:* ^aFour specimens were collected from Yukon territory and were excluded from all analyses. ^bComposed of

116 comprehensive sub-cohort and tracking sub-cohort that recruited participants from seven and 10 provinces,

respectively. ^cComposed of six distinct regional cohorts. AB: Alberta; BC: British Columbia; MB: Manitoba; NB:

118 New Brunswick; NL: Newfoundland and Labrador; NT: Northwest Territories; NS: Nova Scotia; NU: Nunavut;

119 ON: Ontario; PE: Prince Edward Island; QC: Quebec; SK: Saskatchewan; YT: Yukon.

120

121

123 From each dataset, we extracted participants' age, sex, postal code, date of specimen collection, 124 and self-reported race/ethnicity. We used the postal code to classify participants' residence as 125 urban or rural and to assign participants' neighborhood to a quintile of the Pampalon material 126 and social deprivation indices [18]. Material deprivation is a composite measure of education, 127 employment, and income reflecting access to essential material resources. Social deprivation is a 128 composite measure of living alone, single-parent families, and people who are either separated, 129 divorced, and/or widowed, reflecting the fragility of social networks. Both measures are derived 130 from the 2016 Canadian census [19]. We used the date of specimen collection as the sample date 131 when available (CBS, APL); otherwise, we used the date of questionnaire completion (CanPath, 132 CCAHS-1, CLSA) or specimen receipt (Ab-C).

133

134

135 available for the CBS, APL, CCAHS-1, and CLSA studies. Specimen counts for the CCAHS-1 136 study were rounded to base 2000 in accordance with data usage guidelines. Age was calculated 137 as the age at specimen collection (Ab-C, APL, CBS) or questionnaire completion (CanPath, 138 CLSA, CCAHS-1) and categorized as 0-17 years, 18-26 years, 27-36 years, 37-46 years, 47-56 139 years, or 57 years and older. For Ab-C specimens collected between December 2020 – April 140 2021 and July 2021 – September 2021, we used the 2019 baseline age since the age at current 141 collection could not be calculated. We categorized sex as male or female and excluded 142 participants who provided alternative responses (n = 138 [Ab-C]) from analyses involving 143 participant sex. Because race/ethnicity data collection varied between studies and differed from 144 census categorization, we re-classified participants as 'white' and 'racialized minority' and did 145 not analyze specific racialized minority groups (Supplementary Tables S1-S2). For studies

Race/ethnicity information was unavailable for the APL study. Deprivation indices were

146	allowing multiple encounters with participants, we imputed missing variables when available for
147	another encounter (CBS, Ab-C, CLSA). We classified participants who identified as both white
148	and a racialized minority as a racialized minority, and we considered Indigenous identities as a
149	racialized minority but conducted sensitivity analyses with different classifications. Because only
150	CCAHS-1 collected specimens from the capital cities of the Canadian territories, we restricted
151	our primary analysis to specimens collected from Canadian provinces but assessed territorial
152	representativeness for CCAHS-1 separately. We excluded participants who did not meet the
153	inclusion criteria of their respective study and who were missing age, province/territory of
154	residence, or serology test result data. For the CBS study, we did not assess the
155	representativeness of the 0-17-year-old age group because there were no donors younger than 17.
156	We calculated specimen counts using complete cases within each set of demographic strata (e.g.,
157	participants missing race/ethnicity were excluded when stratifying by age, sex, and race/ethnicity
158	but not when stratifying by age, sex, and urbanicity).
159	

160 **Representation ratio analysis**

161 To assess the representativeness of subgroups defined by one or more sociodemographic 162 variable, we derived a *representation ratio* by dividing the proportion of study specimens in a 163 sociodemographic subgroup by the proportion of participants in the subgroup from a target 164 population. A representation ratio less than one indicates the group is underrepresented relative 165 to the target population, and a ratio greater than one indicates overrepresentation. We defined the 166 target subgroup distribution using weighted 2016 Canadian census counts [19], restricting by age 167 and province/territory to match studies' inclusion criteria (Table 1) and rounded to the nearest 168 multiple of zero or five. We calculated representation ratios on unweighted study populations to

169	assess the unadjusted sociodemographic composition of each study except for CCAHS-1, due to
170	guidelines restricting unweighted analyses [6]. For the target distributions, race/ethnicity counts
171	were derived using the census population group variable and Indigenous-identifying respondents
172	were classified as racialized minorities [19]. Indigenous-identifying census respondents were
173	classified as racialized minorities, but were excluded when generating ratios for CLSA and
174	CanPath since Indigenous status was unavailable for most participants. We assessed the impact
175	of excluding Indigenous-identifying census respondents in a second sensitivity analysis. We
176	performed bootstrapping ($n = 5000$) to generate an uncertainty distribution for each
177	representation ratio.
178	
179	Sample count by strata analysis
180	In some cases, statistical adjustment or subsampling may allow derivation of representative
181	population statistics from large, unbalanced study populations if there are sufficient samples
182	from less represented strata [20]. To inform whether this would be feasible in our study
183	populations, we assessed the number of strata with counts greater than 25 when grouped by age,
184	sex, province of residence, urbanicity, race/ethnicity, and date of specimen collection binned into
185	two-month intervals. All analyses were conducted in R version 4.3.1 [21].
186	
187	RESULTS
188	Study population
189	During data pre-processing, we excluded 3,718 observations for CBS (0.4%), 3,871 for APL
190	(1.8%), 2,052 for Ab-C (7.6%), 2,024 for CLSA (10.5%), and 4,258 for CanPath (16.4%) due to
191	missing data or failure to meet inclusion criteria. We analyzed the remaining 1,035,580 (CBS),

192	210,905 (APL), 25,110 (Ab-C), 21,720 (CanPath), 17,310 (CLSA), and 11,050 (CCAHS-1)
193	observations (Supplementary Table S3). For Ab-C, CLSA, and CanPath, the minimum age of
194	participants included in our analysis (Table 1) was older than the minimum age specified in their
195	inclusion criteria [12,15,16]. Across studies, the largest number of observations were in the 57
196	and older age group (34.4% [CCAHS-1] – 91.4% [CLSA]). Observations for the 18-26-year-old
197	age group were generally low $(0.0\%$ [CanPath] – 5.6% [APL]) but were higher for CBS (10.6%)
198	and CCAHS-1 (11.8%). Among studies for which neighborhood deprivation was available,
199	specimen counts across social deprivation quintile were balanced, but only 8.2% (CBS), 8.4%
200	(APL), 9.6% (CLSA), and 13.1% (CCAHS-1) of specimens were provided from the most
201	materially deprived quintile of neighborhoods. Most studies skewed white (78.2% [Ab-C] –
202	94.7% [CLSA]) and female (52.3% [CLSA] – 65.6% [CanPath]), except CBS which skewed
203	white (81.7%) and male (58.2%). Rural specimens accounted for 8.6% (CanPath) – 17.6%
204	(CCAHS-1) of all specimens across studies. Convenience samples collected substantially more
205	specimens for each demographic strata compared to other recruitment strategies (Supplementary
206	Figures S1-S4).

207

208 **Representation ratio analysis**

Studies had reasonable representation across sexes (representation ratio 0.7-1.3; Figure 1) and,
when available, by social deprivation (Supplementary Figure S5). In all studies, racialized
minority subgroups were underrepresented (representation ratio < 1) for some age and sex strata
(Figure 2). Racialized minority representation, while still low, was often better in older age
groups (Ab-C, CanPath, and CLSA), but was better for younger age groups among women for
CBS. Urban regions produced larger representation ratios by age and sex strata than rural regions

215	in all studies (Figures 1-2). While APL had reasonable representation of all material deprivation
216	quintiles and rural residents (representation ratio 0.8-1.3), the CBS population skewed towards
217	less materially deprived neighborhoods and urban regions (though rural representation for CBS
218	was higher than the three longitudinal cohort studies). 18-26-year-old males were
219	underrepresented across most sex and urbanicity strata in all studies for which they were eligible
220	to be sampled.
221	
222	
223	
224	
225	
226	
227	
228	
229	
230	
231	
232	
233	
234	
255	
230	
238	
239	
	11



241 Figure 1: SARS-CoV-2 serological study representativeness by sex, urbanicity, and

racial/ethnic identity. Representativeness was calculated by dividing the proportion of study
specimens collected from a subgroup by the proportion of general population in the subgroup.
Total population counts were estimated using the 2016 Canadian census [19]. Bolded
representation ratios indicate greater than 95% of subgroup bootstrap replicates produced
representation ratios below 0.75. Bootstrapping was not performed for studies with weighted
representation ratios (CCAHS-1).

248

240

249

250





261

262	Among 18-46-year-olds, specimens from the Ab-C open cohort produced larger representation
263	ratios across sex and urbanicity strata compared to CanPath (Figure 2). Representation ratios of
264	18-46-year-old rural residents were generally larger across age and sex strata in CCAHS-1 than
265	several studies with probabilistic recruitment strategies (Ab-C, CanPath). Racialized minorities
266	aged 47 years and older were sufficiently represented (representation ratio 0.8-1.3) in the Ab-C
267	open cohort but were underrepresented in the CanPath and CLSA closed cohorts, except for
268	males aged 57 and older in CanPath. Of the two convenience samples, the CBS study was more
269	representative of participants aged 18-46 across sex and urbanicity strata, whereas the APL study
270	was more representative of individuals aged 47 and older. In CCAHS-1, the only study that
271	sampled in the three Canadian territories, 0-17-year-olds were underrepresented across sexes in
272	territorial specimens (Supplementary Figure S6). Bootstrapping revealed low uncertainty in
273	whether a representation ratio was greater or less than one for most subgroups (Supplementary
274	Figures S7-S13). A sensitivity analysis reclassifying mixed race/ethnicity participants as white
275	had little impact except for the Ab-C cohort, for which 55% of racialized minorities were
276	reclassified as white, leading to lower representation ratios (Supplementary Figures S14-S15).
277	Including Indigenous-identifying individuals as racialized minorities in the representation ratio
278	denominator for studies for which data were unavailable (CLSA and CanPath) had little impact
279	on findings (Supplementary Figure S16).

280

281 Sample count analysis

The convenience samples with large overall sample size produced substantially more cells with counts greater than 25 across 4 levels of stratification compared to all other study designs in the primary analysis (Table 2) and sensitivity analysis (Supplementary Table S4). Pre-existing

285	closed probabilistic cohorts (CLSA, CanPath) produced a greater proportion of cells with counts
286	greater than 25 than other probabilistic recruitment strategies (Ab-C, CCAHS-1) for all strata.
287	
288	
289	
290	
291	
292	
293	
294	
295	
296	
297	
298	
299	
300	
301	
302	
303	
304	
305	
306	

Table 2: Percentage of SARS-CoV-2 serology study demographic subgroups with greater than

308 25 collected specimens.

		Demographic subgroups			
Study (specimen count)	Months sampled	Age, Sex, Province, Month	Age, Sex, Province, Urban, Month	Age, Sex, Province, Race/Ethnicity, Month	Age, Sex, Province, Race/Ethnicity, Urban, Month
CBS blood donor (1,035,580)	41	92%	74%	70%	52%
APL outpatient laboratory (210,905)	27	94%	84%	NA	NA
Ab-C open cohort (25,110)	18	31%	20%	20%	12%
CanPath closed cohort (21,720)	10	40%	31%	32%	26%
CLSA closed cohort (17,310)	11	50%	36%	34%	27%
CCAHS-1 closed cohort (11,050)	6	33%	20%	21%	13%

Notes: Date of sample collection was binned into 2-month intervals for each level of stratification. All

310 specimen counts were unweighted.

317 **DISCUSSION**

318 In this study, we developed a simple method for characterizing study population 319 representativeness and applied it to describe the variability in sociodemographic 320 representativeness across six SARS-CoV-2 serosurveillance studies with diverse recruitment 321 strategies. No study was adequately representative of all sociodemographic subgroups. 322 323 Representation ratios are a flexible diagnostic measure for characterizing study populations. 324 Ratios can consider any combination of characteristics for which reliable estimates of their 325 distribution in a target population are available. Ratios can be used to compare study populations, 326 even when target populations differ, and can be estimated before and after application of sample 327 weights. Notably, representation ratios do not provide insights into the relationship between 328 participant characteristics and a study's estimand, and do not address unmeasured confounding 329 within subgroups.

330

331 Probabilistic surveys have traditionally been considered the 'gold standard' for obtaining 332 representative samples [7]. Use of administrative datasets to construct sampling frames often 333 provides superior population coverage compared to non-probability samples that rely on 334 participant self-selection. The statistical framework also permits estimation of sampling errors 335 and characteristics associated with non-response [22]. While resource constraints may limit the 336 ability of probabilistic designs to perform repeated specimen collection, non-probability 337 sampling within continuous streams of residual blood specimens, such as blood donors, may be 338 more feasible for modelling longitudinal trends, which can also incorporate complex geographic 339 structures [23]. The generalizability of probabilistic designs may also be limited if differences

340 between respondents and non-respondents are non-random [7]. Bias may be introduced via a 341 'healthy volunteer' effect whereby cohort participants are healthier than the general population 342 [24], similar to the 'healthy donor' bias documented in blood donor research cohorts [25]. Where 343 available, response rates of the included studies were fairly low (23% [CCAHS-1], 25% [Ab-C] 344 [6,12]; these response rates exclude individuals who completed a questionnaire but did not 345 provide a blood sample). This suggests non-response bias could partially explain some of the 346 observed differences in representativeness between study designs. The above response rates are 347 consistent with other probabilistic serosurveys [11], although response rates as high as 69% have 348 been reported [10].

349

350 Many large-scale SARS-CoV-2 studies relied on blood donor and healthcare patient populations 351 for serology specimens [22,26]. Blood donors have been discounted as a population for public 352 health surveillance, while the potential for expanded screening of residual outpatient laboratory samples remains unclear. However, we found the representativeness of these convenience 353 354 populations compared favorably to other designs for some sociodemographic dimensions. For 355 low- and middle-income countries with limited operational resources, leveraging residual blood 356 samples may provide a cost-effective avenue to obtain representative data. Future studies should 357 evaluate the potential of linkage to administrative datasets to better characterize 358 representativeness and derive statistical weights for adjustment. Gaps in demographic 359 representation may be overcome by synthesizing data from multiple surveillance streams, though 360 differences in choice of assay, use of venous blood draws or dried blood samples, and the format 361 or availability of variables can curtail the ability to synthesize data across studies [27,28]. 362

363 Racialized minorities were underrepresented across all studies. Language barriers and skepticism 364 of research or medical institutions may contribute to poor representation of some minority 365 groups [29,30]. While use of stratified random sampling or sampling weights may improve 366 sample representativeness, they do not address the underlying individual and societal factors 367 governing participation in health research. Direct engagement and collaboration with community 368 members throughout the research cycle may mitigate recruitment barriers by facilitating trust, 369 reducing misinformation, and ensuring study materials are accessible [30,31]. Racialized 370 minorities may be better represented in healthcare cohorts like APL [32], though a lack of race-371 based data in Canadian administrative healthcare datasets may make this difficult to measure 372 [33]. Notably, representation of racialized minorities improved as age increased in most studies 373 requiring participant opt-in (Ab-C, CLSA, CanPath), but young minorities exhibited better 374 representativeness compared to older subgroups in CBS. Lack of a standardized definition of 375 participant race/ethnicity impeded comparison across studies and prevented assessment of 376 representativeness by specific minority group. 377

378 Several other dimensions of representativeness varied across studies. The Ab-C open cohort was 379 substantially more representative of 18-46-year-olds across sex and urbanicity strata compared to 380 the CanPath longitudinal closed cohort (Figure 2). CLSA and CanPath recruited participants 381 aged 45-85 in 2010 and 35-74 in 2009, respectively, leading to older age distributions for their 382 COVID-19 sub-studies [15,16]. Between convenience samples, individuals residing in highly 383 materially deprived areas were underrepresented when using blood donations (representation 384 ratio 0.4–0.6), but not when using outpatient labs (representation ratio 0.9-1.2). Donor eligibility 385 criteria, along with the 'healthy donor effect' or other unmeasured socioeconomic factors, may

homogenize the demographic composition of the sampled donor pool [25]. Rural regions were consistently underrepresented compared to urban counterparts in all studies, which may be due to urban-centric recruitment patterns or willingness to travel for specimen collection (Figures 1-2).

390 The study had several limitations. First, our analysis considered representativeness by age, sex, 391 race/ethnicity, urbanicity, and neighborhood deprivation. Many other sociodemographic 392 dimensions are important considerations for representativeness in serosurveillance studies, 393 particularly those related to health and disability. We hypothesize a 'healthy participant' 394 sampling bias may have led to underrepresentation of individuals with poor health and/or 395 disability in all study populations except outpatient laboratories [24,25]. Prior analyses of the 396 pre-existing longitudinal cohorts included in our study indicated participants are more educated 397 and/or have higher income than the general population [12,15,16], as are blood donors in the 398 United States [34]. Second, the measurement of race/ethnicity differed between studies. 399 Race/ethnicity options for CBS included four mutually exclusive categories, while the Ab-C, 400 CCAHS-1, CanPath, CLSA, and census datasets permitted selection of multiple racial/ethnic 401 identities. This necessitated dichotomizing the race/ethnicity variable as white or racialized 402 minority and may have biased the CBS representation estimate if individuals who identified as 403 mixed race/ethnicity selected their race/ethnicity as white during donation. Additionally, due to 404 unavailable Indigenous identity data, we modified our representation assessment for the CLSA 405 and CanPath studies by omitting Indigenous-identifying individuals from the census dataset. Our 406 sensitivity analysis suggests this did not substantially impact our findings (Supplementary Figure 407 S16). Third, we restricted our analysis to SARS-CoV-2 serostudies conducted within a single 408 country and used an acceptability level of underrepresentation that is context-specific and open

409	to interpretation. We focused on strata with fewer than 25 samples in our cell count analysis, but
410	this threshold was largely arbitrary. Fourth, we did not analyze factors shaping the
411	sociodemographic composition of each study, including intentional oversampling. For example,
412	CCAHS-1 used a stratified random sampling strategy that oversampled geographic regions with
413	greater COVID-19 prevalence and less populated regions to improve estimate precision. Less
414	populated areas of Canada often have fewer racialized minorities, which likely contributes to
415	lower representation ratios [6]. Understanding the causes and consequences of each study's
416	sociodemographic composition requires more detailed analysis than is presented here. Finally,
417	our study is not a comprehensive assessment of all SARS-CoV-2 serology studies conducted in
418	Canada. Demographic groups excluded here were evaluated elsewhere [35].
419	
420	Understanding variability in demographic representation between study designs is an important
421	consideration when planning serosurveillance studies, which increasingly leverage pre-existing
422	samples or cohorts. This study provides a simple metric to evaluate and compare the
423	representativeness of study populations. We found that underrepresentation of racialized
424	minorities and younger age groups was common and not restricted to convenience samples,
425	which had better representation for some sociodemographic strata. This suggests that
426	representative estimates could be obtained in resource-constrained settings by leveraging lower-
427	cost approaches, such as existing blood or laboratory services, compared to large-scale
428	probabilistically sampled serosurveys. Identifying coverage barriers is vital to support adequate
429	representation and detection of disease trends within demographic subgroups. We also observed
430	differences in the measurement of participant race/ethnicity between studies. This highlights the
431	necessity for consistent, and sufficient, measurement of sociodemographic variables, along with

- 432 the need to adopt a standardized approach to the measurement of self-identified race/ethnicity in
- 433 Canada.
- 434

435 ABBREVIATIONS

436	Ab-C	Action to Beat Coronavirus
437	APL	Alberta Precision Laboratories
438	CanPath	Canadian Partnership for Tomorrow's Health
439	CBS	Canadian Blood Services
440	CCAHS-1	Canadian COVID-19 Antibody and Health Survey 1
441	CLSA	Canadian Longitudinal Study on Aging
442	SARS-CoV-2	Severe acute respiratory syndrome coronavirus-2

443

444 **DECLARATIONS**

445 Ethics approval and consent to participate

- 446 All studies analyzed were approved by a Research Ethics Board or Institutional Review Board of
- 447 a Canadian institution as reported previously. This secondary analysis of six studies was
- 448 approved by the McGill University Faculty of Medicine and Health Sciences Research Ethics
- 449 Board (study number 22-03-077).

450 **Consent for participation**

451 Not applicable.

- 452 Availability of data and materials
- 453 The authors are not authorized to share individual-level data from any study. Processes are
- 454 available for researchers to request access to datasets for studies that have undergone
- 455 institutional ethical approval. Data from Canadian Blood Services and Alberta Precision

- 456 Laboratories may be made available upon request, subject to internal review, privacy legislation,
- 457 data sharing agreements, and research ethics approval. The CCAHS-1 study by Statistics Canada
- 458 can be analyzed for approved projects at Research Data Centres located across Canada
- 459 (https://www.statcan.gc.ca/en/microdata/data-centres/access). Data are available from the
- 460 Canadian Longitudinal Study on Aging (www.clsa-elcv.ca) for researchers who meet the criteria
- 461 for access to de-identified CLSA data. Access to the Ab-C study data can be requested through
- the COVID-19 Immunity Task Force Databank (https://portal.citf.mcgill.ca/). Access to the
- 463 CanPath data can be requested through the CanPath data portal (https://portal.canpath.ca/).
- 464 Analytical code will be available in a public repository upon publication.

465 **Competing interests**

- 466 The authors declare that they have no competing interests.
- 467 Funding
- WAR was supported by funding from Canadian Blood Services and the COVID-19 ImmunityTask Force.

470 Authors' contributions

- 471 MJK and WAR designed the study with input from DLB, SFO, and CC. MJK, YY, and JC
- 472 contributed to data analysis. MJK and WAR drafted the initial manuscript. All
- 473 authors revised the manuscript and approved the final version.

474 Acknowledgements

- 475 This research was made possible using data collected by Canadian Blood Services' SARS-CoV-
- 476 2 Seroprevalence Study; the Canadian Partnership for Tomorrow's Health (CanPath formerly
- 477 CPTP) COVID-19 Antibody study and its regional cohorts the BC Generations Project, Alberta's
- 478 Tomorrow Project, the Ontario Health Study, CARTaGENE, Manitoba Tomorrow Project and

479	the Atlantic Partnership for Tomorrow's Health; the Action to Beat Coronavirus in Canada (Ab-
480	C) study; the Alberta Precision Laboratories study; the Canadian COVID-19 Antibody and
481	Health Survey (CCAHS) conducted by Statistics Canada, and the Canadian Longitudinal Study
482	on Aging (CLSA). We thank the participants, staff, and researchers of all six studies. We also
483	thank Scott McLeish for the insightful discussions which greatly improved the quality of the
484	manuscript. Funding for the CLSA is provided by the Government of Canada through the
485	Canadian Institutes of Health Research (CIHR) under grant reference: LSA 94473 and the
486	Canada Foundation for Innovation, as well as the provinces, Newfoundland, Nova Scotia,
487	Quebec, Ontario, Manitoba, Alberta, and British Columbia. Funding for support of the CLSA
488	COVID-19 questionnaire-based study is provided by the Juravinski Research Institute, Faculty of
489	Health Sciences, McMaster University, the Provost Fund from McMaster University, the
490	McMaster Institute for Research on Aging, the Public Health Agency of Canada/CIHR grant
491	reference CMO 174125 and the government of Nova Scotia. This research has been conducted
492	using the CLSA Baseline Comprehensive Dataset v7.0, Baseline Tracking Dataset v4.0, Follow-
493	up 1 Comprehensive Dataset v4.0, Follow-up 1 Tracking Dataset v3.0, Follow-up 2
494	Comprehensive Dataset v1.0, Follow-up 2 Tracking Dataset v1.0, COVID-19 Questionnaire
495	Study Dataset v1.1, and COVID-19 Seroprevalence Study Dataset v1.0 under Application
496	Number 2209005. The CLSA is led by Drs. Parminder Raina, Christina Wolfson, and Susan
497	Kirkland. We appreciate the funding that made each study possible, including the support each
498	study received from the Government of Canada through the COVID-19 Immunity Task Force.
499	The opinions expressed in this manuscript are the author's own and do not reflect the views of
500	the data providers and/or their institutions.

501

502 **REFERENCES**

503	1.	O'Brien SF.	. Caffrey	/ N. Yi (DL. et al.	Cross-Canada	Variabilit	v in Blood Donor S	SARS-
			, /		x — 7				

- 504 CoV-2 Seroprevalence by Social Determinants of Health. Microbiology Spectrum.
- 505 2023;11(1):e03356-22. 10.1128/spectrum.03356-22
- 506 2. Charlton CL, Nguyen LT, Bailey A, et al. Pre-Vaccine Positivity of SARS-CoV-2
- 507 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
- 508 Microbiology Spectrum. 2021;9(1):e00291-21. 10.1128/Spectrum.00291-21
- 509 3. Jha, Prabhat. Action to beat Coronavirus study: Dataset contributed to the CITF
- 510 Databank. Version DRAFT. Borealis. https://doi.org/doi:10.5683/SP3/LA2IKO
- 511 4. Canadian Longitudinal Study on Aging. Data Support Document SARS-CoV-2
 512 Antibadiae 2024
- 512 Antibodies. 2024.
- 513 5. Canadian Partnership for Tomorrow's Health. COVID-19 initiatives. CanPath Canadian
- 514 Partnership for Tomorrow's Health. Available from: https://canpath.ca/covid-19-initiatives/.
- 515 6. Statistics Canada. Canadian COVID-19 Antibody and Health Survey (CCAHS). 2020.
- 516 Available from:
- 517 https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&Id=1287991
- 518 7. Cornesse C, Bosnjak M. Is there an association between survey characteristics and
- 519 representativeness? A meta-analysis. Survey Research Methods. 2018;12(1):1-13.
- 520 10.18148/srm/2018.v12i1.7205
- 521 8. Offergeld R, Preußel K, Zeiler T, et al. Monitoring the SARS-CoV-2 Pandemic:
- 522 Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in

- 523 Germany—Results from the SeBluCo Study 2020–2022. Pathogens. 2023;12(4):551.
- 524 10.3390/pathogens12040551
- 525 9. Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey of SARS-
- 526 CoV-2 IgG antibodies, Greece, March and April 2020. Eurosurveillance.
- 527 2020;25(31):2001369. 10.2807/1560-7917.ES.2020.25.31.2001369
- 528 10. Pérez-Gómez B, Pastor-Barriuso R, Fernández-de-Larrea N, et al. SARS-CoV-2
- 529 Infection During the First and Second Pandemic Waves in Spain: The ENE–COVID Study.
- 530 Am J Public Health. 2023;113(5):533-544. 10.2105/AJPH.2023.307233
- 531 11. Ward H, Atchison C, Whitaker M, et al. Design and Implementation of a National
- 532 Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-
- 533 Testing: The REACT-2 Study. Am J Public Health. 2023;113(11):1201-1209.
- 534 10.2105/AJPH.2023.307381
- 535 12. Tang X, Sharma A, Pasic M, et al. Assessment of SARS-CoV-2 Seropositivity During
- the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults. JAMA

537 Network Open. 2022;5(2):e2146798. 10.1001/jamanetworkopen.2021.46798

- 538 13. Patel EU, Bloch EM, Tobian AAR. Severe Acute Respiratory Syndrome Coronavirus 2
- 539 Serosurveillance in Blood Donor Populations. The Journal of Infectious Diseases.
- 540 2022;225(1):1-4. 10.1093/infdis/jiab517
- 541 14. Rudolph JE, Zhong Y, Duggal P, et al. Defining representativeness of study samples in
- 542 medical and population health research. BMJ Med. 2023;2(1):e000399. 10.1136/bmjmed-
- 543 2022-000399

544	15.	Raina P.	Wolfson C.	. Kirkland S.	et al.	Cohort P	rofile: '	The (Canadian	Longitu	ıdinal	Stud	V
			,		,								

- on Aging (CLSA). International Journal of Epidemiology. 2019;48(6):1752-1753j.
- 546 10.1093/ije/dyz173
- 547 16. Dummer TJB, Awadalla P, Boileau C, et al. The Canadian Partnership for Tomorrow
- 548 Project: A pan-Canadian platform for research on chronic disease prevention. CMAJ.
- 549 2018;190(23):E710-E717. 10.1503/cmaj.170292
- 550 17. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
- 551 Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting
- observational studies. Epidemiology. 2007;18(6):800-804.
- 553 18. Pampalon R, Hamel D, Gamache P, et al. An area-based material and social deprivation
- index for public health in Québec and Canada. Can J Public Health. 2012;103(8 Suppl
- 555 2):S17-22. 10.1007/BF03403824
- 556 19. Statistics Canada. Census Profile, 2016 Census. 2017. Available from:
- 557 https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/index.cfm?Lang=E
- 558 20. Downes M, Carlin JB. Multilevel regression and poststratification as a modeling
- approach for estimating population quantities in large population health studies: A simulation
- 560 study. Biometrical Journal. 2020;62(2):479-491. 10.1002/bimj.201900023
- 561 21. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
- 562 Austria: R Foundation for Statistical Computing; 2023. https://www.R-project.org/.
- 563 22. Lindan CP, Desai M, Boothroyd D, et al. Design of a population-based longitudinal
- 564 cohort study of SARS-CoV-2 incidence and prevalence among adults in the San Francisco
- 565 Bay Area. Annals of Epidemiology. 2022;67:81-100. 10.1016/j.annepidem.2021.11.001

566 2	23. N	Yu Y,	Knight MJ.	Gibson D.	et al. Te	mporal tr	rends in o	lisparities in	COVID-19
-------	-------	-------	------------	-----------	-----------	-----------	------------	----------------	----------

- seropositivity among Canadian blood donors. International Journal of Epidemiology.
- 568 2024;53(3):dyae078. 10.1093/ije/dyae078
- 569 24. Froom P, Melamed S, Kristal-Boneh E, et al. Healthy Volunteer Effect in Industrial
- 570 Workers. Journal of Clinical Epidemiology. 1999;52(8):731-735. 10.1016/S0895-

571 4356(99)00070-0

- 572 25. Atsma F, Veldhuizen I, Verbeek A, et al. Healthy donor effect: Its magnitude in health
- 573 research among blood donors. Transfusion. 2011;51(8):1820-1828. doi:10.1111/j.1537-
- 574 2995.2010.03055.x
- 575 26. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large
- 576 nationwide sample of patients on dialysis in the USA: A cross-sectional study. *The Lancet*.

577 2020;396(10259):1335-1344. doi:10.1016/S0140-6736(20)32009-2

- 578 27. Mulchandani R, Brown B, Brooks T, et al. Use of dried blood spot samples for SARS-
- 579 CoV-2 antibody detection using the Roche Elecsys ® high throughput immunoassay. Journal
- 580 of Clinical Virology. 2021;136:104739. 10.1016/j.jcv.2021.104739
- 581 28. Patel EU, Bloch EM, Clarke W, et al. Comparative Performance of Five Commercially
- 582 Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals
- 583 with High Neutralizing Titers. Journal of Clinical Microbiology.
- 584 2021;59(2):10.1128/jcm.02257-20. 10.1128/jcm.02257-20
- 585 29. Etti M, Fofie H, Razai M, et al. Ethnic minority and migrant underrepresentation in
- 586 Covid-19 research: Causes and solutions. eClinicalMedicine. 2021;36.
- 587 10.1016/j.eclinm.2021.100903

588	30.	Bonevski B	, Randell M.	Paul C.	, et al.	Reaching	the hard	-to-reach: A	A systematic	review	of
			,	/	/	<u> </u>			/		

- 589 strategies for improving health and medical research with socially disadvantaged groups.
- 590 BMC Medical Research Methodology. 2014;14(1):42. 10.1186/1471-2288-14-42
- 591 31. Ekezie W, Czyznikowska BM, Rohit S, et al. The views of ethnic minority and
- 592 vulnerable communities towards participation in COVID-19 vaccine trials. Journal of Public
- 593 Health. 2021;43(2):e258-e260. 10.1093/pubmed/fdaa196
- 32. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large
- 595 nationwide sample of patients on dialysis in the USA: A cross-sectional study. The Lancet.
- 596 2020;396(10259):1335-1344. 10.1016/S0140-6736(20)32009-2
- 597 33. Khan MM, Kobayashi K, Vang ZM, et al. Are visible minorities "invisible" in Canadian
- health data and research? A scoping review. International Journal of Migration, Health and
- 599 Social Care. 2017;13(1):126-143. 10.1108/IJMHSC-10-2015-0036
- 600 34. Patel EU, Bloch EM, Grabowski MK, et al. Sociodemographic and behavioral
- 601 characteristics associated with blood donation in the United States: A population-based
- 602 study. Transfusion. 2019;59(9):2899-2907. 10.1111/trf.15415
- 603 35. Atkinson A, Albert A, McClymont E, et al. Canadian SARS-CoV-2 serological survey
- 604 using antenatal serum samples: A retrospective seroprevalence study. Canadian Medical
- 605 Association Open Access Journal. 2023;11(2):E305-E313. 10.9778/cmajo.20220045